Shana Wingo, MD, discusses advancements being made in the field of surgery for patients with gynecologic cancers.
Danielle Bucco
Articles by Danielle Bucco
Researchers at Dana-Farber Cancer Institute have identified an exceptional responder to pembrolizumab – a treatment-naïve patient with metastatic uterine leiomyosarcoma who had a complete tumor remission for more than 2 years on the PD-1 inhibitor.
Robert Dreicer, MD, discusses emerging treatments for patients with advanced mCRPC.
John L. Marshall, MD, discusses efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.
Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.
A recent study found 12 new genetic variants were found that increase the risk of developing the disease and confirmed the association of 18 previously discovered variants.
Adam M. Brufsky, MD, PhD, discusses considerations for using the bone-targeted agents denosumab and zoledronic acid in patients with breast cancer.
Stephan Grupp, MD, PhD, discusses results of the phase II ELIANA study and the next steps with CAR T-cell therapy in ALL.
Susan F. Slovin, MD, PhD, offers her expert insight on the current state of immunotherapy in prostate cancer.
Sara Hurvitz, MD, discusses ongoing advances that continue to revolutionize the treatment of patients with HER2+ breast cancer.
Dmitriy Zamarin, MD, PhD, discusses the next steps necessary to advance immunotherapy in the field of gynecologic cancers.
Sara A. Hurvitz, MD, discusses the pros and cons of anthracycline treatment.
Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab as well as zoledronic acid as in patients with breast cancer.
Arturo Loaiza-Bonilla, MD, the potential role of <em>BRAF</em> and <em>CTNNB1</em> mutations in the survival difference between CRC patients with left- and right-sided tumors.
The investigational compound 5-imino-13-deoxydoxorubicin showed promising activity in patients with metastatic and nonresectable soft tissue sarcoma.
The much anticipated initial results of the Gynecologic Oncology Group 252 trial failed to provide additional clarity for the use of intravenous versus intraperitoneal chemotherapy in patients with ovarian cancer.
A novel approach has been developed by researchers at the University of Michigan to treating patients with advanced laryngeal cancer with the hope of improving historical survival rates of 50% to 60% in this setting.
External beam radiation therapy (EBRT) lowers the risk of local recurrence in patients with either retroperitoneal or extremity sarcomas.
The findings from a phase II study of intermittent sunitinib in patients with previously untreated mRCC demonstrate that periodic extended sunitinib treatment breaks are feasible and the clinical efficacy does not seem to be compromised.
H. Jack West, MD, discusses the benefits of EGFR TKIs in NSCLC, challenges with determining optimal sequencing, and potential combinations on the horizon.
According to results of a phase I trial, the addition of the CDK 4/6 inhibitor palbociclib can help patients with mantle cell lymphoma overcome resistance to the BTK inhibitor ibrutinib.
Saad Z. Usmani, MD, discusses the POLLUX update and PAVO findings presented at ASH, as well as the latest developments with daratumumab.
Elizabeth Plimack, MD, discusses the 2-year updated data from the CheckMate-025 trial in RCC, as well as the remaining questions with nivolumab in this setting.
The combination of the Fc-modified monoclonal antibody margetuximab with chemotherapy may offer a new treatment option for patients with HER2-positive metastatic breast cancer.
Targeted therapies and immunotherapy are revolutionizing oncology, however, chemotherapy retains a key role in the treatment of advanced prostate cancer, with recent data showing profound benefits with docetaxel in newly diagnosed patients.